secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2024-06-07T23:59:59+00:00
Accession:  0001104659-24-069605
Event type: regulatory
Sentiment:  positive
Materiality: 0.45
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode Therapeutics regains Nasdaq minimum bid price compliance; hearing cancelled
--------------------------------------------------------------------------------

- Received Nasdaq letter on June 3, 2024 confirming compliance with Listing Rule 5550(a)(2).
- Hearing scheduled for June 25, 2024 has been cancelled.
- Remains under mandatory panel monitor through January 27, 2025.
- Ticker RNAZ; stock continues on Nasdaq Capital Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465924069605/0001104659-24-069605-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465924069605/tm2416749d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-069605

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer